SBIR Phase I: Development of a Eukaryotic Membrane Protein Overexpression System

这项小型企业创新第一阶段的研究集中在为真核细胞膜蛋白创建过表达技术，这是一组仍然难以处理但具有重要医学意义的膜蛋白。 大多数膜蛋白很难大量获得，即使是毫克级，因为它们的天然生物合成水平通常很低，目前可用的蛋白表达方法对膜蛋白无效。随着几个基因组测序计划的完成，许多大规模的努力正在进行中，以了解蛋白质产品。这项研究的更广泛的影响是显着的表面膜蛋白的结构为基础的药物设计和蛋白质工程，蛋白质治疗和诊断设备。这些努力将为膜蛋白提供新的理解，并导致新一代的有效药物，用于几乎所有的治疗领域，包括传染病，癌症，由于膜蛋白遗传缺陷引起的遗传疾病，中枢神经系统疾病，心血管系统疾病，消化系统疾病和许多其他疾病。

This Small Business Innovation Phase I research concentrates on creating overexpression technology for eukaryotic membrane proteins, a group of membrane proteins that remain intractable yet are of significant medical importance. A majority of membrane proteins are very difficult to obtain in significant quantity, even at milligram scale, since their natural biosynthesis levels often are very low and currently available protein expression methods are not effective for membrane proteins. With the completion of several genome sequencing projects, many large-scale efforts are under way to understand the protein products.The broader impacts of this research are significant in surface membrane proteins for structure-based drug design and protein engineering, protein therapeutics, and diagnostic devices. These efforts will provide new understanding of membrane proteins as well as lead to new generations of efficacious medicines for virtually all therapeutic areas including infectious diseases, cancer, genetic diseases due to genetic defect in membrane proteins, central nervous system diseases, cardiovascular system diseases, digestive system diseases and many others.